UOC
UBS O'Connor Portfolio holdings
AUM
$1.93B
1-Year Return
38.75%
This Quarter Return
+10.85%
1 Year Return
+38.75%
3 Year Return
+182.42%
5 Year Return
+480.25%
10 Year Return
+1,573.29%
AUM
$3.16B
AUM Growth
-$2.43B
(-44%)
Cap. Flow
-$2.83B
Cap. Flow
% of AUM
-89.49%
Top 10 Holdings %
Top 10 Hldgs %
61.23%
Holding
616
New
86
Increased
50
Reduced
239
Closed
136
Top Buys
| 1 |
PXD
Pioneer Natural Resource Co.
PXD
|
$579M |
| 2 |
SPLK
Splunk Inc
SPLK
|
$454M |
| 3 |
HES
Hess
HES
|
$334M |
| 4 |
SRC
SPIRIT REALTY CAPITAL, INC.
SRC
|
$120M |
| 5 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$73.1M |
Top Sells
Sector Composition
| 1 | Energy | 29.73% |
| 2 | Technology | 22.08% |
| 3 | Healthcare | 10.58% |
| 4 | Real Estate | 7.31% |
| 5 | Industrials | 4.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SAVE
326
DELISTED
Spirit Airlines, Inc.
SAVE
| $492K | 0.02% |
30,000
-1,117,771
| -97% | -$18.3M |
|
327
Kenvue
KVUE
$35.7B
| $481K | 0.02% |
22,336
-254,010
| -92% | -$5.47M |
|
328
Charles River Laboratories
CRL
$8.07B
| $481K | 0.02% |
2,034
-1,177
| -37% | -$278K |
|
329
Essex Property Trust
ESS
$17.3B
| $471K | 0.01% |
1,900
+100
| +6% | +$24.8K |
|
330
IQVIA
IQV
$31.9B
| $470K | 0.01% |
2,030
-2,605
| -56% | -$603K |
|
331
Ovid Therapeutics
OVID
$87.5M
| $465K | 0.01% |
144,500
-5,500
| -4% | -$17.7K |
|
332
BioNTech
BNTX
$27B
| $460K | 0.01% |
4,363
+363
| +9% | +$38.3K |
|
333
Acrivon Therapeutics
ACRV
$41.8M
| $460K | 0.01% |
93,443
-11,557
| -11% | -$56.9K |
|
334
Quanterix
QTRX
$211M
| $459K | 0.01% |
16,794
-12,406
| -42% | -$339K |
|
335
AvalonBay Communities
AVB
$27.8B
| $456K | 0.01% |
+2,435
| New | +$456K |
|
|
SLRN
336
DELISTED
ACELYRIN
SLRN
| $448K | 0.01% |
+60,000
| New | +$448K |
|
337
BioAtla
BCAB
$31.5M
| $444K | 0.01% |
180,423
-262,299
| -59% | -$645K |
|
338
Zscaler
ZS
$42.7B
| $443K | 0.01% |
2,000
-28,000
| -93% | -$6.2M |
|
339
AtriCure
ATRC
$1.76B
| $435K | 0.01% |
12,199
-37,094
| -75% | -$1.32M |
|
340
SCYNEXIS
SCYX
$37.3M
| $423K | 0.01% |
189,467
-176,552
| -48% | -$394K |
|
341
Lucid Motors
LCID
$5.66B
| $421K | 0.01% |
+10,000
| New | +$421K |
|
342
Viking Therapeutics
VKTX
$3.03B
| $412K | 0.01% |
22,141
-35,764
| -62% | -$666K |
|
343
Minerva Neurosciences
NERV
$16.4M
| $398K | 0.01% |
64,644
-5,356
| -8% | -$32.9K |
|
344
Phathom Pharmaceuticals
PHAT
$875M
| $394K | 0.01% |
43,209
-74,071
| -63% | -$676K |
|
345
Marathon Digital Holdings
MARA
$5.63B
| $393K | 0.01% |
+16,749
| New | +$393K |
|
346
PMV Pharmaceuticals
PMVP
$77.4M
| $391K | 0.01% |
+126,000
| New | +$391K |
|
347
Altimmune
ALT
$334M
| $386K | 0.01% |
+34,298
| New | +$386K |
|
348
Evolv Technologies Holdings, Inc. Warrant
EVLVW
$11.6M
| $380K | 0.01% |
478,241
-214,959
| -31% | -$171K |
|
349
Tesla
TSLA
$1.13T
| $373K | 0.01% |
1,500
-1,000
| -40% | -$248K |
|
350
BioCryst Pharmaceuticals
BCRX
$1.74B
| $360K | 0.01% |
60,159
-181,661
| -75% | -$1.09M |
|